葛兰素史克：新冠药物Sotrovimab对奥密克戎毒株依旧有效_老虎社区_美港股上老虎

葛兰素史克：新冠药物Sotrovimab对奥密克戎毒株依旧有效

新浪财经2021-12-08

当地时间周二（12月7日），英国制药公司葛兰素史克宣布，该公司与Vir Biotechnology合作开发的新冠抗体药物Sotrovimab对奥密克戎变异毒株有效。受此消息提振，Vir盘前一度大涨逾10%。试验数据显示，Sotrovimab能够抵抗奥密克戎变异毒株的所有刺突蛋白突变，而不仅仅是关键突变。测试包含了迄今在刺突蛋白中发现的所有37个突变。葛兰素史克上周就表示，Sotrovimab对...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

SDLiuSG
·2021-12-08
66
回复
1
举报
收起
- SDLiuSG:
  cc
  2021-12-08
  回复
  举报

热议股票

7x24

全部

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/2189965850?lang=zh_CN&edition=full","thumbnail":"https://static.tigerbbs.com/3d4fcdee67f247de200a76d36a5c57c6","is_english":false,"pubTime":"2021-12-08 01:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2189965850","market":"us","top_or_hot":-1,"title":"葛兰素史克：新冠药物Sotrovimab对奥密克戎毒株依旧有效","media":"新浪财经","content":"<div>\n<p>当地时间周二（12月7日），英国制药公司葛兰素史克宣布，该公司与Vir Biotechnology合作开发的新冠抗体药物Sotrovimab对奥密克戎变异毒株有效。受此消息提振，Vir盘前一度大涨逾10%。\n试验数据显示，Sotrovimab能够抵抗奥密克戎变异毒株的所有刺突蛋白突变，而不仅仅是关键突变。测试包含了迄今在刺突蛋白中发现的所有37个突变。\n葛兰素史克上周就表示，Sotrovimab对...</p>\n\n<a href=\"https://finance.sina.com.cn/stock/usstock/c/2021-12-08/doc-ikyakumx2654219.shtml\">网页链接</a>\n\n</div>\n","source":"sina_us","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>葛兰素史克：新冠药物Sotrovimab对奥密克戎毒株依旧有效</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n葛兰素史克：新冠药物Sotrovimab对奥密克戎毒株依旧有效\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-08 01:00 北京时间&nbsp;&nbsp;&nbsp;<a href=https://finance.sina.com.cn/stock/usstock/c/2021-12-08/doc-ikyakumx2654219.shtml><strong>新浪财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>当地时间周二（12月7日），英国制药公司葛兰素史克宣布，该公司与Vir Biotechnology合作开发的新冠抗体药物Sotrovimab对奥密克戎变异毒株有效。受此消息提振，Vir盘前一度大涨逾10%。\n试验数据显示，Sotrovimab能够抵抗奥密克戎变异毒株的所有刺突蛋白突变，而不仅仅是关键突变。测试包含了迄今在刺突蛋白中发现的所有37个突变。\n葛兰素史克上周就表示，Sotrovimab对...</p>\n\n<a href=\"https://finance.sina.com.cn/stock/usstock/c/2021-12-08/doc-ikyakumx2654219.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4532","symbol_name":"文艺复兴科技持仓","start_time":0,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2021-12-08/doc-ikyakumx2654219.shtml","article_id":"2189965850","we_media_id":null,"thumbnails":["https://static.tigerbbs.com/3d4fcdee67f247de200a76d36a5c57c6"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2189965850","pubTimestamp":1638896420,"sourceInfo":{"source_id":"sina_us","name":"新浪美股"},"weMediaInfo":null,"summary":"财联社 讯，当地时间周二，英国制药公司葛兰素史克宣布，该公司与Vir Biotechnology合作开发的新冠抗体药物Sotrovimab对奥密克戎变异毒株有效。受此消息提振，Vir盘前一度大涨逾10%。　　试验数据显示，Sotrovimab能够抵抗奥密克戎变异毒株的所有刺突蛋白突变，而不仅仅是关键突变。　　葛兰素史克上周就表示，Sotrovimab对奥密克戎毒株的关键突变有效，而最新测试提供了更多的确定性。","collect":0,"end_time":0,"defaultTopTitle":"sina.com.cn","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4532":"文艺复兴科技持仓","GSK":"葛兰素史克","GSK.UK":"葛兰素史克","BK4007":"制药"},"translate_title":"GlaxoSmithKline: COVID-19 drug Sotrovimab is still effective against Omicron strain","themeId":null,"isJumpTheme":false,"ttsUrl":"https://static.tigerbbs.com/f46d65e4ab5ae26cd47336255afc9802","symbols_score_info":{"GSK":0.9,"GSK.UK":0.9},"content_text":"当地时间周二（12月7日），英国制药公司葛兰素史克宣布，该公司与Vir Biotechnology合作开发的新冠抗体药物Sotrovimab对奥密克戎变异毒株有效。受此消息提振，Vir盘前一度大涨逾10%。\n试验数据显示，Sotrovimab能够抵抗奥密克戎变异毒株的所有刺突蛋白突变，而不仅仅是关键突变。测试包含了迄今在刺突蛋白中发现的所有37个突变。\n葛兰素史克上周就表示，Sotrovimab对奥密克戎毒株的关键突变有效，而最新测试提供了更多的确定性。\nVir首席执行官George Scangos周二表示，Sotrovimab面对奥密克戎毒株的效果有所减弱，但差异并不显著，相信该药物能继续为患者的早期治疗提供好处，以避免最严重的后果。\nSotrovimab目前已在大约12个国家获得批准，其中就包括美国，在试验中，该抗体药物可将轻至中度新冠患者的住院和死亡风险降低79%。\n尽管注射抗体只是新冠肺炎治疗手段中的一种，但对免疫受到抑制、对疫苗没有充分反应的群体而言，它发挥着关键作用，有助于减轻病毒对更容易出现重症的患者的影响。\n研究人员正在抓紧测试现有的疫苗和药物针对奥密克戎的有效性，南非上周披露的报告显示，感染奥密克戎的患者可能只会出现较轻的病症，但也有科学家警告称，现在下结论还为时过早。","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":606434176,"gmtCreate":1638918955176,"gmtModify":1638918955299,"author":{"id":"3575949053778392","authorId":"3575949053778392","name":"SDLiuSG","avatar":"https://static.tigerbbs.com/00bc0903e8bbdc107f07a92f947eccbe","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3575949053778392","authorIdStr":"3575949053778392"},"htmlText":"66","listText":"66","text":"66","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/606434176","repostId":2189965850,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6889690,"gmtCreate":1638918961770,"gmtModify":1638918961859,"authorId":3575949053778392,"author":{"id":3575949053778392,"idStr":"3575949053778392","authorId":3575949053778392,"name":"SDLiuSG","avatar":"https://static.tigerbbs.com/00bc0903e8bbdc107f07a92f947eccbe","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":606434176,"type":1,"supId":0,"prevId":0,"content":"<u>cc</u>","text":"<u>cc</u>","html":"<u>cc</u>"}],"langContent":"CN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":7,"commentSize":1,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}